Has Samuel Caughron, MD received payments from drug or device companies?

Yes. Drug and device makers reported $620,885 in general payments to Samuel Caughron, MD across 588 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Samuel Caughron, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Samuel Caughron, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Samuel Caughron, MD

Anatomic Pathology & Clinical Pathology · N Kansas City, MONPI 1538216353

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $398,286 of the $620,885 with a category attached, or 64.1%. 19 manufacturers reported payments, led by AstraZeneca at 40.9% of the total. Reporting peaked in 2019 at $179,727 and has fallen 51.1% since, to $87,895 in 2025. Among anatomic pathology & clinical pathology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$620,885in general payments, 2019–2025

Across 588 payments — averaging $1055.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$254K
Genentech USA, Inc.$124K
Lilly USA, LLC$86K
Merck$78K
E.r. Squibb & Sons, L.L.C.$21K
Takeda Pharmaceuticals U.S.A., Inc.$14K
plus $45K from 13 others

$16,625in research payments, 2019–2025

Across 1 payment — averaging $16,625 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Promega Corporation$17K

What the payments were for

Consulting fees$125,35320%
Speaking & faculty fees$398,28664%
Travel & lodging$87,58514%
Food & beverage$9,0671%
Gifts$5810%
Entertainment$130%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	237	$253,803
Genentech USA, Inc.	103	$123,800
Lilly USA, LLC	118	$85,781
Merck	61	$78,005
E.r. Squibb & Sons, L.L.C.	20	$20,820
Takeda Pharmaceuticals U.S.A., Inc.	11	$14,045
AbbVie	10	$9,989
Astrazeneca UK Limited	2	$7,983
Eli Lilly	3	$7,188
Johnson & Johnson	4	$5,251
Sanofi	3	$3,759
Partner Therapeutics, Inc.	2	$3,675
Roche Diagnostics Corporation	2	$3,465
Illumina, Inc.	6	$1,659
Pfizer	1	$1,375
Bayer	2	$192
Novartis	1	$65
Varian Medical Systems, Inc.	1	$17
Siemens Medical Solutions USA, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LYNPARZA$121,132
TAGRISSO$76,005
KEYTRUDA$72,167
EXKIVITY$8,758
Enhertu$5,673
Truqap$5,649
Avastin$5,243
Herceptin$5,243
Lucentis$5,243
Rituxan$5,243
Tamiflu$5,243
RYBREVANT$5,153
Erleada$5,153
AKEEGA$5,153
Elahere$4,600
Bizengri$3,675
BENCHMARK SPECIAL STAINS WASH II$2,900
IMFINZI$2,575
NovaSeq 6000Dx Sequencer Instrument$1,588
TALZENNA$1,375

How this compares

$620,885 in reported general payments places this provider in the 95th percentile of 169 anatomic pathology & clinical pathology providers in Missouri.

See all anatomic pathology & clinical pathology providers in Missouri →

Medicare billing

Part B allowed, 2024

$1,992

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in N Kansas City

David SmidSpringfield$6.8M
Eric DuncavageSaint Louis$112K
Alan LugerColumbia$88K
Danielle CarpenterSaint Louis$27K
John RolloSaint Louis$16K
Xiuli LiuSaint Louis$16K
Jon RitterSaint Louis$16K
Adam BoothSaint Louis$15K
Daniela HermelinSaint Louis$10K
Elizabeth BruntSaint Louis$6K

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →